HealthLeaders Media February 22, 2023
The company prioritizes unmet needs for women in contraception, fertility, and vaginal and sexual health.
KEY TAKEAWAYS
In January, Daré Bioscience announced topline PK results from its Phase 1 / 2 clinical trial of DARE-HRT1, an estradiol and progesterone intravaginal ring for hormone therapy.
Also in January, Daré requested the FDA to allow DARE-HRT1 to advance into single Phase 3 efficacy trial .
Johnson founded Daré based on business sense and a passion for women’s health needs.
Sabrina Martucci Johnson never planned on being a founder and CEO of a women’s healthcare company, but after identifying gaps in women’s healthcare, she asked herself, “If not me, then who?”
“I’m not one of those people who...
Today's Sponsors
Today's Sponsor